Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab plus nab-paclitaxel and carboplatin versus nab-paclitaxel and carboplatin as first-line treatment for advanced driver-negative non-small cell lung cancer
ChiCTR1900026321Phase 2Recruiting
- Sponsor
- The First People's Hospital of Yueyang
- Start
- Oct 2019
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of camrelizumab, paclitaxel and carboplatin in non-small cell lung cancer (NSCLC) (2 arms), sponsored by The First People's Hospital of Yueyang. Primary endpoints: Objective response rate, Disease control rate and 1 more. Started Oct 2019; status: recruiting.
02
Drugs
camrelizumabpaclitaxelcarboplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR1900026321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900026321.